PCRX logo

Pacira BioSciences (PCRX) CAPEX

PCRX Annual CAPEX

$15.16 M
-$14.91 M-49.59%

31 December 2023

1-Year Change

-49.59%
PCRX annual capital expenditures is down -49.59% year-on-year

3-Year Change

-59.89%
PCRX annual capital expenditures is down -59.89% over the past 3 years

All-time High

$45.87 M
PCRX annual capital expenditures is currently -66.95% below its historical high of $45.87 million

Sector Rank

69.95%
PCRX annual capital expenditures is higher than 69.95% of companies in Healthcare sector
Annual FCF$139.49 M
PCRX annual free cash flow is $139.49 million
Annual CFO$154.65 M
PCRX annual cash flow from operations is $154.65 million
Annual CFI$77.54 M
PCRX annual cash flow from investing activities is $77.54 million
Annual CFF-$183.03 M
PCRX annual cash flow from financing activities is -$183.03 million

PCRX CAPEX Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PCRX Quarterly CAPEX

$4.09 M
+$2.50 M+157.36%

30 September 2024

1-Year Change

+20.57%
PCRX quarterly capital expenditures is up +20.57% year-on-year

3-Year Change

-46.64%
PCRX quarterly capital expenditures is down -46.64% over the past 3 years

All-time High

$14.41 M
PCRX quarterly capital expenditures is currently -71.60% below its historical high of $14.41 million

Sector Rank

70.37%
PCRX quarterly capital expenditures is higher than 70.37% of companies in Healthcare sector
Quarterly FCF$49.83 M
PCRX quarterly free cash flow is $49.83 million
Quarterly CFO$53.92 M
PCRX quarterly cash flow from operations is $53.92 million
Quarterly CFI-$52.16 M
PCRX quarterly cash flow from investing activities is -$52.16 million
Quarterly CFF-$2.85 M
PCRX quarterly cash flow from financing activities is -$2.85 million

PCRX Quarterly CAPEX Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PCRX TTM CAPEX

$10.32 M
+$698.00 K+7.26%

30 September 2024

1-Year Change

-45.29%
PCRX TTM capital expenditures is down -45.29% year-on-year

3-Year Change

-74.5%
PCRX TTM capital expenditures is down -74.5% over the past 3 years

All-time High

$51.11 M
PCRX TTM capital expenditures is currently -79.82% below its historical high of $51.11 million

Sector Rank

65.1%
PCRX TTM capital expenditures is higher than 65.1% of companies in Healthcare sector
TTM FCF$193.53 M
PCRX TTM free cash flow is $193.53 million
TTM CFO$203.84 M
PCRX TTM cash flow from operations is $203.84 million
TTM CFI-$74.53 M
PCRX TTM cash flow from investing activities is -$74.53 million
TTM CFF$17.54 M
PCRX TTM cash flow from financing activities is $17.54 million

PCRX TTM CAPEX Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PCRX CAPEX Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-49.6%+20.6%-45.3%
3 y3 years-59.9%-46.6%-74.5%
5 y5 years+4.5%-46.6%-74.5%

PCRX CAPEX High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-67.0%at low-65.1%+157.4%-77.5%+7.3%
5 y5-year-67.0%+49.2%-71.6%+157.4%-79.8%+7.3%
alltimeall time-67.0%+175.2%-71.6%+881.3%-79.8%+2373.9%

Pacira BioSciences CAPEX History

DateAnnualQuarterlyTTM
Sept 2024
-
$4.09 M(+157.4%)
$10.32 M(+7.3%)
June 2024
-
$1.59 M(-43.9%)
$9.62 M(-15.9%)
Mar 2024
-
$2.84 M(+57.7%)
$11.43 M(-24.6%)
Dec 2023
$15.16 M(-49.6%)
$1.80 M(-47.0%)
$15.16 M(-19.6%)
Sept 2023
-
$3.39 M(-0.3%)
$18.86 M(-8.7%)
June 2023
-
$3.40 M(-48.1%)
$20.64 M(-28.8%)
Mar 2023
-
$6.57 M(+19.5%)
$28.97 M(-3.7%)
Dec 2022
$30.08 M(-34.4%)
$5.49 M(+6.0%)
$30.08 M(-10.9%)
Sept 2022
-
$5.18 M(-55.9%)
$33.75 M(-19.0%)
June 2022
-
$11.73 M(+53.0%)
$41.65 M(+2.9%)
Mar 2022
-
$7.67 M(-16.3%)
$40.46 M(-11.8%)
Dec 2021
$45.87 M(+21.3%)
$9.17 M(-29.9%)
$45.87 M(-10.3%)
Sept 2021
-
$13.08 M(+23.9%)
$51.11 M(+11.6%)
June 2021
-
$10.55 M(-19.3%)
$45.80 M(+3.7%)
Mar 2021
-
$13.07 M(-9.3%)
$44.15 M(+16.8%)
Dec 2020
$37.80 M(+272.1%)
$14.41 M(+85.6%)
$37.80 M(+35.5%)
Sept 2020
-
$7.76 M(-12.8%)
$27.89 M(+28.4%)
June 2020
-
$8.91 M(+32.5%)
$21.72 M(+46.1%)
Mar 2020
-
$6.72 M(+49.5%)
$14.87 M(+46.3%)
Dec 2019
$10.16 M(-30.0%)
$4.50 M(+182.5%)
$10.16 M(+28.5%)
Sept 2019
-
$1.59 M(-22.4%)
$7.91 M(-26.6%)
June 2019
-
$2.05 M(+1.7%)
$10.77 M(-5.1%)
Mar 2019
-
$2.02 M(-10.0%)
$11.35 M(-21.8%)
Dec 2018
$14.51 M(-24.7%)
$2.24 M(-49.6%)
$14.51 M(-16.3%)
Sept 2018
-
$4.45 M(+69.1%)
$17.35 M(-5.3%)
June 2018
-
$2.63 M(-49.2%)
$18.31 M(-12.1%)
Mar 2018
-
$5.18 M(+2.1%)
$20.83 M(+8.1%)
Dec 2017
$19.27 M
$5.08 M(-6.3%)
$19.27 M(+1.0%)
Sept 2017
-
$5.42 M(+5.1%)
$19.07 M(+8.6%)
June 2017
-
$5.16 M(+42.6%)
$17.56 M(-17.5%)
DateAnnualQuarterlyTTM
Mar 2017
-
$3.62 M(-25.9%)
$21.27 M(-13.9%)
Dec 2016
$24.71 M(-38.7%)
$4.88 M(+25.0%)
$24.71 M(-14.5%)
Sept 2016
-
$3.91 M(-56.0%)
$28.91 M(-20.8%)
June 2016
-
$8.87 M(+25.7%)
$36.51 M(-7.5%)
Mar 2016
-
$7.05 M(-22.3%)
$39.47 M(-2.0%)
Dec 2015
$40.30 M(+75.3%)
$9.08 M(-21.1%)
$40.30 M(+0.6%)
Sept 2015
-
$11.51 M(-2.8%)
$40.03 M(+21.8%)
June 2015
-
$11.83 M(+50.3%)
$32.86 M(+21.5%)
Mar 2015
-
$7.87 M(-10.8%)
$27.05 M(+17.7%)
Dec 2014
$22.98 M(+88.8%)
$8.82 M(+103.8%)
$22.98 M(+35.5%)
Sept 2014
-
$4.33 M(-28.1%)
$16.96 M(-2.1%)
June 2014
-
$6.02 M(+58.2%)
$17.33 M(+32.8%)
Mar 2014
-
$3.81 M(+35.8%)
$13.05 M(+7.2%)
Dec 2013
$12.17 M(-33.3%)
$2.80 M(-40.3%)
$12.17 M(-13.7%)
Sept 2013
-
$4.70 M(+169.9%)
$14.10 M(-10.0%)
June 2013
-
$1.74 M(-40.7%)
$15.66 M(-14.4%)
Mar 2013
-
$2.93 M(-38.0%)
$18.29 M(+0.2%)
Dec 2012
$18.26 M(+196.0%)
$4.73 M(-24.4%)
$18.26 M(+14.0%)
Sept 2012
-
$6.26 M(+43.3%)
$16.01 M(+40.4%)
June 2012
-
$4.37 M(+50.5%)
$11.40 M(+38.4%)
Mar 2012
-
$2.90 M(+16.8%)
$8.24 M(+33.5%)
Dec 2011
$6.17 M(-8.9%)
$2.48 M(+50.6%)
$6.17 M(-7.0%)
Sept 2011
-
$1.65 M(+37.1%)
$6.63 M(-3.6%)
June 2011
-
$1.20 M(+44.6%)
$6.88 M(-4.2%)
Mar 2011
-
$832.00 K(-71.8%)
$7.18 M(+6.1%)
Dec 2010
$6.77 M(+22.9%)
$2.95 M(+55.4%)
$6.77 M(+77.2%)
Sept 2010
-
$1.90 M(+26.0%)
$3.82 M(+98.7%)
June 2010
-
$1.51 M(+261.2%)
$1.92 M(+361.2%)
Mar 2010
-
$417.00 K
$417.00 K
Dec 2009
$5.51 M(-5.7%)
-
-
Dec 2008
$5.84 M
-
-

FAQ

  • What is Pacira BioSciences annual capital expenditures?
  • What is the all time high annual CAPEX for Pacira BioSciences?
  • What is Pacira BioSciences annual CAPEX year-on-year change?
  • What is Pacira BioSciences quarterly capital expenditures?
  • What is the all time high quarterly CAPEX for Pacira BioSciences?
  • What is Pacira BioSciences quarterly CAPEX year-on-year change?
  • What is Pacira BioSciences TTM capital expenditures?
  • What is the all time high TTM CAPEX for Pacira BioSciences?
  • What is Pacira BioSciences TTM CAPEX year-on-year change?

What is Pacira BioSciences annual capital expenditures?

The current annual CAPEX of PCRX is $15.16 M

What is the all time high annual CAPEX for Pacira BioSciences?

Pacira BioSciences all-time high annual capital expenditures is $45.87 M

What is Pacira BioSciences annual CAPEX year-on-year change?

Over the past year, PCRX annual capital expenditures has changed by -$14.91 M (-49.59%)

What is Pacira BioSciences quarterly capital expenditures?

The current quarterly CAPEX of PCRX is $4.09 M

What is the all time high quarterly CAPEX for Pacira BioSciences?

Pacira BioSciences all-time high quarterly capital expenditures is $14.41 M

What is Pacira BioSciences quarterly CAPEX year-on-year change?

Over the past year, PCRX quarterly capital expenditures has changed by +$698.00 K (+20.57%)

What is Pacira BioSciences TTM capital expenditures?

The current TTM CAPEX of PCRX is $10.32 M

What is the all time high TTM CAPEX for Pacira BioSciences?

Pacira BioSciences all-time high TTM capital expenditures is $51.11 M

What is Pacira BioSciences TTM CAPEX year-on-year change?

Over the past year, PCRX TTM capital expenditures has changed by -$8.54 M (-45.29%)